OmniAb (OABI) Interest & Investment Income (2022 - 2026)
OmniAb (OABI) reported Interest & Investment Income of $487000.0 for Q1 2026, down 9.31% year-over-year from $537000.0 in Q1 2025, and down 60.24% on a QoQ basis from $1.2 million in Q4 2025.
OmniAb (OABI) has 5 years of Interest & Investment Income data on file, last reported at $487000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 9.31% year-over-year to $487000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 2.17% YoY) and the FY2025 annual result came in at $2.7 million, down 14.36% from the prior year.
- Interest & Investment Income eased to $487000.0 in Q1 2026 per OABI's latest filing, from $1.2 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.3 million in Q1 2023 and bottomed at $436000.0 in Q2 2025.
- The 5-year median for Interest & Investment Income is $738000.0 (2024), against an average of $849642.9.
- The widest annual swing landed in 2023, when Interest & Investment Income surged 101.19%; it then plunged 45.38% in 2024.
- Tracing OABI's Interest & Investment Income over 5 years: stood at $587000.0 in 2022, then surged by 101.19% to $1.2 million in 2023, then plunged by 44.54% to $655000.0 in 2024, then soared by 87.02% to $1.2 million in 2025, then sank by 60.24% to $487000.0 in 2026.
- Per Business Quant, the three latest OABI Interest & Investment Income figures stand at $487000.0 (Q1 2026), $1.2 million (Q4 2025), and $462000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 487,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 487,000.00 |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | 462,000.00 |
| Jun 30, 2025 | 436,000.00 |
| Mar 31, 2025 | 537,000.00 |
| Dec 31, 2024 | 655,000.00 |
| Sep 30, 2024 | 691,000.00 |
| Jun 30, 2024 | 785,000.00 |
| Mar 31, 2024 | 975,000.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.29 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 587,000.00 |